Drug Trial Radar · NCT05684965
XTX301 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
358
Planned (sponsor's estimate)
Start
May 11, 2023
Primary completion
Sep 2028
Study completion Sep 2028
Sponsor
- Lead sponsor
- Xilio Development, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
XTX301Drug
XTX301 monotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose Limiting Toxicities (DLTs) (Part 1A only)Time frame: From the first dose of the study drug at Cycle 1 Day 1 up to next applicable cycle visit (Cycle 2 Day 1 or Cycle 3 Day 1). Approximately 21 to 42 days. Each cycle is 21 days.
- Incidence of treatment-emergent adverse events (TEAEs) and changes in clinical laboratory valuesTime frame: Up to 24 months
- Investigator-assessed objective response rate (ORR) per RECIST 1.1 (for all Phase 2 disease specific cohorts except CRPC/APMR-PC)Time frame: up to 24 months
- PSA50 response rate and Investigator-assessed ORR per RECIST 1.1 by CT/MRI for patients with measurable disease (for Phase 2 CRPC/APMR-PC cohort only)Time frame: up to 24 months
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
University of California, Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
Yale Cancer Center
New Haven, Connecticut · Recruiting
HealthPartners Frauenshuh Cancer center
Saint Louis Park, Minnesota · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
The Gabrail Pharmacology Phase 1 Research Center
Canton, Ohio · Recruiting
University Hospital Cleveland Medical Center
Cleveland, Ohio · Recruiting
The Ohio State University Wexner Medical Center
Columbus, Ohio · Recruiting
University of Pittsburgh Medical Center-Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Tranquil Clinical Research
Webster, Texas · Completed
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Sheboygan Cancer & Blood Specialists
Sheboygan, Wisconsin · Withdrawn
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.